Carry-over in pre-dose samples for steady state BE [Study As­sess­ment]

posted by hirenpharm – Ahmedabad, 2019-03-29 21:56 (1647 d 07:56 ago) – Posting: # 20103
Views: 4,218

Hello everyone,

We did a multiple dose (5 weeks, 1 TDS patch every week) bioequivalence study. The BE was assessed at week 5 at steady state. It was a 3-period study. In period 2 and 3, we observed some carry-over from the previous period treatments. I remember, the 5% of Cmax rule for single-dose studies. But, can someone please throw some light on how to handle this carry-over in multiple dose steady state studies? Does the carry-over in week 1 pre-dose really impact week 5 steady state parameters? any regulatory guidance/published articles will be really helpful.

Edit: Category changed; see also this post #1[Helmut]

Dr. Hiren Mehta

Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,628 registered users;
17 visitors (0 registered, 17 guests [including 4 identified bots]).
Forum time: 06:53 CEST (Europe/Vienna)

The object of statistics is information.
The objective of statistics is the understanding of information
contained in data.    Irwin and Marylees Miller

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz